Latest Commercialization News

Elixir Energy has initiated fracture stimulation and flow testing at its Diona-1 well in Queensland’s Surat-Bowen Basin, aiming to confirm a larger gas resource footprint within the Taroom Trough. The well’s proximity to existing infrastructure offers a swift route to market if results prove positive.

EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.

ECS Botanics reports a third straight quarter of positive operating cash flow, driven by strong B2C growth and strategic international shipments to Germany and New Zealand.

Antipa Minerals completed its CY2025 drilling program at the Minyari Gold-Copper Project, revealing new high-grade zones and boosting its Mineral Resource Estimate to 3.6 million ounces gold equivalent. The company is progressing its Pre-Feasibility Study and has commenced a major new drilling campaign, supported by a strong cash position.

Castile Resources has kicked off pilot plant bench scale testing for its Rover 1 project, integrating a 41% resource upgrade and higher metal prices into its Bankable Feasibility Study. The company also secured $8.4 million in funding and is preparing for exploration drilling amid regional consolidation.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

The Federal Court has imposed a $1.55 million penalty on Money3 Loans, a Solvar subsidiary, for limited breaches of the National Consumer Credit Act between 2019 and 2021. Solvar highlights strengthened governance and underwriting since the period in question.

Raiden Resources is pushing forward with its Crixás Gold Tailings Project in Brazil, planning a 1,000m drilling program to establish a JORC Mineral Resource Estimate and aiming for a Final Investment Decision with less than A$1 million in preliminary costs. Meanwhile, exploration at its Vuzel Gold Project in Bulgaria progresses with permitting for a silver anomaly drill program.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Nido Education has expanded its footprint with a $9.1 million acquisition of four child care services, adding 348 places and an estimated $1.9 million annualised EBITDA. The company is also actively pursuing further acquisitions beyond its incubation pipeline amid sector demand challenges.

Brazilian Rare Earths (ASX: BRE) has reported substantial expansion of its Monte Alto rare earth project with ultra high-grade drilling results and validated low-temperature processing delivering 97% recovery. The company also secured a Trial Mining Licence enabling early production and bulk shipments.